RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Oxford Biomedica Stock

Oxford Biomedica P/E 2024

Oxford Biomedica P/E

-7.69

Ticker

OXB.L

ISIN

GB00BDFBVT43

WKN

A2JLRX

As of Aug 2, 2024, Oxford Biomedica's P/E ratio was -7.69, a 175.63% change from the -2.79 P/E ratio recorded in the previous year.

The Oxford Biomedica P/E history

Oxford Biomedica Aktienanalyse

What does Oxford Biomedica do?

Oxford BioMedica PLC is a biopharmaceutical company based in Oxford, England. The company was founded in 1995 and has since become a leading provider of gene therapy products. The company's business model is to develop, produce, and market gene therapies for rare diseases and cancer. Oxford BioMedica utilizes modern technologies, such as viral vectors, to introduce genetic material into diseased cells and correct their function. One of the company's main areas of focus is the development of gene therapies for rare diseases. Oxford BioMedica has several promising products in this field, including gene therapies for metabolic disorders, muscular diseases, and eye diseases. Another important area for the company is the development of cancer immunotherapies. Oxford BioMedica is working on the development of gene therapies that activate the body's immune system to specifically target cancer cells. Among the products that Oxford BioMedica has already brought to market is the gene therapy product Strimvelis, which is used to treat severe combined immunodeficiency (SCID). Through treatment with Strimvelis, children with SCID can lead a normal life and are no longer confined to sterile environments. Another well-known product from Oxford BioMedica is the gene therapy product OXB-102, which is being tested in phase III clinical trials for the treatment of Parkinson's disease. In this therapy, a viral vector is used to correct a genetic mutation in the affected brain cells and alleviate the symptoms of Parkinson's. In recent years, Oxford BioMedica has also formed significant partnerships with major pharmaceutical and biotech companies such as Novartis, Sanofi, and Bioverativ to further develop and bring its gene therapy technology and products to market. Overall, Oxford BioMedica is a leading company in the field of gene therapy. With a strong pipeline of promising products and significant partnerships with the pharmaceutical industry, the company is well positioned to continue growing and contribute to the cure of diseases. Oxford Biomedica ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Oxford Biomedica's P/E Ratio

The Price to Earnings (P/E) Ratio of Oxford Biomedica is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Oxford Biomedica's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Oxford Biomedica is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Oxford Biomedica’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Oxford Biomedica stock

What is the price-to-earnings ratio of Oxford Biomedica?

The price-earnings ratio of Oxford Biomedica is currently -7.69.

How has the price-earnings ratio of Oxford Biomedica changed compared to last year?

The price-to-earnings ratio of Oxford Biomedica has increased by 175.63% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Oxford Biomedica high compared to other companies?

Yes, the price-to-earnings ratio of Oxford Biomedica is high compared to other companies.

How does an increase in the price-earnings ratio of Oxford Biomedica affect the company?

An increase in the price-earnings ratio of Oxford Biomedica would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Oxford Biomedica affect the company?

A decrease in the price-earnings ratio of Oxford Biomedica would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Oxford Biomedica?

Some factors that influence the price-earnings ratio of Oxford Biomedica are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Oxford Biomedica pay?

Over the past 12 months, Oxford Biomedica paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oxford Biomedica is expected to pay a dividend of 0 GBP.

What is the dividend yield of Oxford Biomedica?

The current dividend yield of Oxford Biomedica is .

When does Oxford Biomedica pay dividends?

Oxford Biomedica pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oxford Biomedica?

Oxford Biomedica paid dividends every year for the past 0 years.

What is the dividend of Oxford Biomedica?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oxford Biomedica located?

Oxford Biomedica is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oxford Biomedica kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oxford Biomedica from 8/2/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 8/2/2024.

When did Oxford Biomedica pay the last dividend?

The last dividend was paid out on 8/2/2024.

What was the dividend of Oxford Biomedica in the year 2023?

In the year 2023, Oxford Biomedica distributed 0 GBP as dividends.

In which currency does Oxford Biomedica pay out the dividend?

The dividends of Oxford Biomedica are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Oxford Biomedica stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Oxford Biomedica

Our stock analysis for Oxford Biomedica Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oxford Biomedica Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.